However, all kidney diseases have a metabolic component, even if it is secondary to an autoimmune, infectious, genetic or other cause, so other types of CKD were studied in the DAPA-CKD and EMPA ...

Last year, Jardiance achieved encouraging results in the EMPA-REG OUTCOME trial, which found that Jardiance reduced the risk of new-onset and worsening kidney disease by 39% in adults with ...

The approval is based on results from EMPA-KIDNEY, billed as the largest and broadest dedicated SGLT2 inhibitor trial in CKD to date, which showed a significant benefit of Jardiance in reducing ...